 BOSTON, March 07, 2022 GLOBE NEWSWIRE -- Ikena Oncology, Inc. Nasdaq: IKNA, a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will participate in an oral presentation highlighting the companys novel TEAD inhibitor, IK-930, at the American Association for Cancer Research AACR 2022 Annual Meeting. 